Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-11-11
DOI
10.3389/fonc.2021.746976
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
- (2021) Xianbin Wu et al. Cancer Cell International
- Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.
- (2020) Sara Elena Rebuzzi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
- (2020) Robert J. Motzer et al. CANCER
- Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-Free Survival in Post-Nephrectomy High-Risk Loco-Regional RCC: Analysis of the S-TRAC Trial
- (2020) Anup Patel et al. CLINICAL CANCER RESEARCH
- The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study
- (2020) Naotaka Nishiyama et al. BMC Urology
- Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma
- (2019) Beihe Wang et al. International Braz J Urol
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
- (2019) Ugo De Giorgi et al. CLINICAL CANCER RESEARCH
- Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis
- (2019) Vincenzo Di Nunno et al. Immunotherapy
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Tumour-associated neutrophils in patients with cancer
- (2019) Merav E. Shaul et al. Nature Reviews Clinical Oncology
- Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
- (2019) Hiroki Ishihara et al. Targeted Oncology
- C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab
- (2019) Kotaro Suzuki et al. International Journal of Clinical Oncology
- 1255PNeutrophil to lymphocyte ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N)
- (2019) A Simonaggio et al. ANNALS OF ONCOLOGY
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- C-reactive protein to albumin ratio predicts the outcome in renal cell carcinoma: A meta-analysis
- (2019) Wei Zhou et al. PLoS One
- Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: A systematic review and meta-analysis
- (2019) Shiqiang Su et al. International Journal of Surgery
- Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
- (2018) Tao Jiang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
- (2018) Mehmet Asim Bilen et al. Clinical Genitourinary Cancer
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
- (2018) Aly-Khan A. Lalani et al. Journal for ImmunoTherapy of Cancer
- High neutrophil to lymphocyte ratio is associated with poor outcome during immunotherapy treatment in metastatic renal cell carcinoma.
- (2018) Rohit K. Jain et al. JOURNAL OF CLINICAL ONCOLOGY
- Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab
- (2018) Haris Zahoor et al. Journal for ImmunoTherapy of Cancer
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review
- (2017) Romain Boissier et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
- (2017) Ghayathri Jeyakumar et al. Journal for ImmunoTherapy of Cancer
- Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
- (2017) Michael R. Cassidy et al. EBioMedicine
- Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells
- (2016) Katrin Moses et al. SEMINARS IN IMMUNOLOGY
- Cancer-related inflammation and treatment effectiveness
- (2014) Connie I Diakos et al. LANCET ONCOLOGY
- Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy
- (2014) Yong Park et al. SpringerPlus
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
- (2013) Graeme J.K. Guthrie et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Distribution of metastatic sites in renal cell carcinoma: a population-based analysis
- (2011) M. Bianchi et al. ANNALS OF ONCOLOGY
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Activated macrophages promote Wnt signalling through tumour necrosis factor-α in gastric tumour cells
- (2008) Keisuke Oguma et al. EMBO JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now